Tinzaparin is a low-molecular-weight heparin (LMWH) with antithrombotic properties. It has FDA-approved labeling for use in the treatment of acute symptomatic deep-vein thrombosis (DVT ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

Low molecular weight heparin (LMWH) is an anticoagulant injected subcutaneously or intravenously and acts via activation of antithrombin III which in turn inactivates thrombin and factor Xa to ...

Because of differences in manufacturing processes, anti-factor Xa and anti-factor IIa properties, and molecular weight distributions, tinzaparin cannot be used interchangeably with other LMWHs or UFH.